Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded at Cantor Fitzgerald
Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) to a strong-buy rating in a report published on Thursday morning,Zacks.com reports. Several other equities research analysts have also recently commented on the stock. Robert W. Baird boosted their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock […]
Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) to a strong-buy rating in a report published on Thursday morning,Zacks.com reports. Several other equities research analysts have also recently commented on the stock. Robert W. Baird boosted their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock […]
